


## AZD-5069

<b>Cat. No.:</b>	HY-19855		
<b>CAS No.:</b>	878385-84-3		
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>22</sub> F <sub>2</sub> N <sub>4</sub> O <sub>5</sub> S <sub>2</sub>		
<b>Molecular Weight:</b>	476.52		
<b>Target:</b>	CXCR		
<b>Pathway:</b>	GPCR/G Protein; Immunology/Inflammation		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 90 mg/mL (188.87 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
<b>1 mM</b>	2.0985 mL	10.4927 mL	20.9855 mL
<b>5 mM</b>	0.4197 mL	2.0985 mL	4.1971 mL
<b>10 mM</b>	0.2099 mL	1.0493 mL	2.0985 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 50% PEG300 >> 50% saline  
Solubility: 12.5 mg/mL (26.23 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline  
Solubility: 2.62 mg/mL (5.50 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for cancer treatment.

#### IC<sub>50</sub> & Target

<sup>125</sup>I-IL-8-CXCR2

## In Vitro

AZD-5069 (Compound 2) acts as CXCR2 antagonist by inhibition of [<sup>125</sup>I]-IL-8 binding to human CXCR2 receptors and as inhibitor of GRO $\alpha$ -induced Ca<sup>2+</sup> flux in human neutrophils loaded with fluo-3 dye<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Nat Commun. 2022 Feb 16;13(1):890.
- J Extracell Vesicles. 2023 Jul;12(7):e12342.
- Cell Rep. 2023 Nov 13;42(11):113424.
- J Med Chem. 2024 Apr 25;67(8):6327-6343.
- J Cereb Blood Flow Metab. 2023 May 17;271678X231175190.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Norman P, et al. Evidence on the identity of the CXCR2 antagonist AZD-5069. Expert Opin Ther Pat. 2013 Jan;23(1):113-7.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA